Clearmind Medicine Raises $1.6M in Direct Offering
Ticker: CMND · Form: 6-K · Filed: Dec 3, 2025 · CIK: 1892500
Sentiment: neutral
Topics: capital-raise, direct-offering, common-shares
TL;DR
Clearmind Medicine just sold 16M shares at $0.10 for $1.6M gross. Offering closed Dec 3, 2025.
AI Summary
On December 3, 2025, Clearmind Medicine Inc. entered into a securities purchase agreement for a registered direct offering. The company will sell 16,000,000 common shares at a price of $0.10 per share, raising gross proceeds of $1,600,000.
Why It Matters
This capital raise provides Clearmind Medicine with funds to continue its operations and potentially advance its pharmaceutical development pipeline.
Risk Assessment
Risk Level: medium — The company is conducting a registered direct offering, which can dilute existing shareholders and may indicate a need for immediate capital.
Key Numbers
- $1.6M — Gross Proceeds (Raised from the sale of 16,000,000 common shares at $0.10 each in a registered direct offering.)
- 16,000,000 — Common Shares Sold (Offered and sold in a registered direct offering at $0.10 per share.)
- $0.10 — Price Per Share (The price at which common shares were sold in the registered direct offering.)
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- December 3, 2025 (date) — Date of securities purchase agreement and offering
- 16,000,000 (dollar_amount) — Number of common shares sold
- $0.10 (dollar_amount) — Purchase price per common share
- $1,600,000 (dollar_amount) — Gross proceeds from the offering
FAQ
What was the total amount of gross proceeds raised by Clearmind Medicine in the registered direct offering?
Clearmind Medicine raised gross proceeds of $1,600,000 from the sale of 16,000,000 common shares at $0.10 per share.
When did Clearmind Medicine enter into the securities purchase agreement for this offering?
Clearmind Medicine entered into the securities purchase agreement on December 3, 2025.
How many common shares did Clearmind Medicine agree to sell in the registered direct offering?
The company agreed to sell 16,000,000 of its common shares.
What was the purchase price per common share in the offering?
The purchase price per common share was $0.10.
What type of offering was this for the sale of common shares?
The sale of common shares was conducted as a registered direct offering.
Filing Stats: 784 words · 3 min read · ~3 pages · Grade level 13 · Accepted 2025-12-03 06:06:35
Key Financial Figures
- $0.10 — Offering”) at a purchase price of $0.10 per Common Share. The Offering is expe
- $1.6 million — ompany are expected to be approximately $1.6 million. The Company expects to use the net pro
Filing Documents
- ea0268174-6k_clearmind.htm (6-K) — 19KB
- ea026817401ex5-1_clearmind.htm (EX-5.1) — 22KB
- ea026817401ex10-1_clearmind.htm (EX-10.1) — 187KB
- ex5-1_001.jpg (GRAPHIC) — 3KB
- ex5-1_002.jpg (GRAPHIC) — 1KB
- 0001213900-25-117537.txt ( ) — 234KB
Forward Looking Statements
Forward Looking Statements This Report of on Form 6-K contains statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward looking statements are based upon the Company’s present intent, beliefs or expectations, but forward looking statements are not guaranteed to occur and may not occur for various reasons, including some reasons which are beyond the Company’s control. For example, this Report states that the Offering is expected to close on or about December 4, 2025. In fact, the closing of the Offering is subject to various conditions and contingencies as are customary in securities purchase agreements in the United States. If these conditions are not satisfied or the specified contingencies do not occur, this Offering may not close. For this reason, among others, you should not place undue reliance upon the Company’s forward looking statements. Except as required by law, the Company undertakes no obligation to revise or update any forward looking statements in order to reflect any event or circumstance that may arise after the date of this Report on Form 6-K. 1 EXHIBIT INDEX Exhibit No. 5.1 Opinion of Daniel N. Bloch, Canadian counsel to the Company 10.1 Form of Securities Purchase Agreement 23.1 Consent of Daniel N. Bloch (included in Exhibit 5.1) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: December 3, 2025 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3